Endogenous Opioids Inhibit Early-Stage Pancreatic Pain in a Mouse Model of Pancreatic Cancer

Molly A. Sevcik, Beth M. Jonas, Theodore H. Lindsay, Kyle G. Halvorson, Joseph R. Ghilardi, Michael A. Kuskowski, Pinku Mukherjee, John E. Maggio, Patrick W Mantyh

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background & Aims: The endogenous opioid system is involved in modulating the experience of pain, the response to stress, and the action of analgesic therapies. Recent human imaging studies have shown a significant tonic modulation of visceral pain, raising the question of whether endogenous opioids tonically modulate the pain of visceral cancer. Methods: Transgenic mice expressing the first 127 amino acids of simian virus 40 large T antigen, under the control of the rat elastase-1 promoter, that spontaneously develop pancreatic cancer were used to investigate the role of endogenous opioids in the modulation of pancreatic cancer pain. Visceral pain behaviors were assessed as degree of hunching and vocalization. Results Although mice with late-stage pancreatic cancer displayed spontaneous, morphine-reversible, visceral pain-related behaviors such as hunching and vocalization, these behaviors were absent in mice with early-stage pancreatic cancer. After systemic administration of the central nervous system (CNS)-penetrant opioid receptor antagonists naloxone or naltrexone, mice with early-stage pancreatic cancer displayed significant visceral pain-related behaviors, whereas systemic administration of the CNS-nonpenetrant opioid antagonist naloxone-methiodide did not induce an increase in visceral pain behaviors. Conclusions Our findings suggest that a CNS opioid-dependent mechanism tonically modulates early and late-stage pancreatic cancer pain. Understanding the mechanisms that mask this pain in early stage disease and drive this pain in late-stage disease may allow improved diagnosis, treatment, and care of patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)900-910
Number of pages11
JournalGastroenterology
Volume131
Issue number3
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Visceral Pain
Pancreatic Neoplasms
Opioid Analgesics
Pain
Narcotic Antagonists
Central Nervous System
Naltrexone
Simian virus 40
Pancreatic Elastase
Viral Tumor Antigens
Naloxone
Masks
Morphine
Transgenic Mice
Analgesics
Patient Care
Amino Acids
Therapeutics
Cancer Pain

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sevcik, M. A., Jonas, B. M., Lindsay, T. H., Halvorson, K. G., Ghilardi, J. R., Kuskowski, M. A., ... Mantyh, P. W. (2006). Endogenous Opioids Inhibit Early-Stage Pancreatic Pain in a Mouse Model of Pancreatic Cancer. Gastroenterology, 131(3), 900-910. https://doi.org/10.1053/j.gastro.2006.06.021

Endogenous Opioids Inhibit Early-Stage Pancreatic Pain in a Mouse Model of Pancreatic Cancer. / Sevcik, Molly A.; Jonas, Beth M.; Lindsay, Theodore H.; Halvorson, Kyle G.; Ghilardi, Joseph R.; Kuskowski, Michael A.; Mukherjee, Pinku; Maggio, John E.; Mantyh, Patrick W.

In: Gastroenterology, Vol. 131, No. 3, 09.2006, p. 900-910.

Research output: Contribution to journalArticle

Sevcik, MA, Jonas, BM, Lindsay, TH, Halvorson, KG, Ghilardi, JR, Kuskowski, MA, Mukherjee, P, Maggio, JE & Mantyh, PW 2006, 'Endogenous Opioids Inhibit Early-Stage Pancreatic Pain in a Mouse Model of Pancreatic Cancer', Gastroenterology, vol. 131, no. 3, pp. 900-910. https://doi.org/10.1053/j.gastro.2006.06.021
Sevcik MA, Jonas BM, Lindsay TH, Halvorson KG, Ghilardi JR, Kuskowski MA et al. Endogenous Opioids Inhibit Early-Stage Pancreatic Pain in a Mouse Model of Pancreatic Cancer. Gastroenterology. 2006 Sep;131(3):900-910. https://doi.org/10.1053/j.gastro.2006.06.021
Sevcik, Molly A. ; Jonas, Beth M. ; Lindsay, Theodore H. ; Halvorson, Kyle G. ; Ghilardi, Joseph R. ; Kuskowski, Michael A. ; Mukherjee, Pinku ; Maggio, John E. ; Mantyh, Patrick W. / Endogenous Opioids Inhibit Early-Stage Pancreatic Pain in a Mouse Model of Pancreatic Cancer. In: Gastroenterology. 2006 ; Vol. 131, No. 3. pp. 900-910.
@article{6f46fe7dbb034bed8336098214fa65a6,
title = "Endogenous Opioids Inhibit Early-Stage Pancreatic Pain in a Mouse Model of Pancreatic Cancer",
abstract = "Background & Aims: The endogenous opioid system is involved in modulating the experience of pain, the response to stress, and the action of analgesic therapies. Recent human imaging studies have shown a significant tonic modulation of visceral pain, raising the question of whether endogenous opioids tonically modulate the pain of visceral cancer. Methods: Transgenic mice expressing the first 127 amino acids of simian virus 40 large T antigen, under the control of the rat elastase-1 promoter, that spontaneously develop pancreatic cancer were used to investigate the role of endogenous opioids in the modulation of pancreatic cancer pain. Visceral pain behaviors were assessed as degree of hunching and vocalization. Results Although mice with late-stage pancreatic cancer displayed spontaneous, morphine-reversible, visceral pain-related behaviors such as hunching and vocalization, these behaviors were absent in mice with early-stage pancreatic cancer. After systemic administration of the central nervous system (CNS)-penetrant opioid receptor antagonists naloxone or naltrexone, mice with early-stage pancreatic cancer displayed significant visceral pain-related behaviors, whereas systemic administration of the CNS-nonpenetrant opioid antagonist naloxone-methiodide did not induce an increase in visceral pain behaviors. Conclusions Our findings suggest that a CNS opioid-dependent mechanism tonically modulates early and late-stage pancreatic cancer pain. Understanding the mechanisms that mask this pain in early stage disease and drive this pain in late-stage disease may allow improved diagnosis, treatment, and care of patients with pancreatic cancer.",
author = "Sevcik, {Molly A.} and Jonas, {Beth M.} and Lindsay, {Theodore H.} and Halvorson, {Kyle G.} and Ghilardi, {Joseph R.} and Kuskowski, {Michael A.} and Pinku Mukherjee and Maggio, {John E.} and Mantyh, {Patrick W}",
year = "2006",
month = "9",
doi = "10.1053/j.gastro.2006.06.021",
language = "English (US)",
volume = "131",
pages = "900--910",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Endogenous Opioids Inhibit Early-Stage Pancreatic Pain in a Mouse Model of Pancreatic Cancer

AU - Sevcik, Molly A.

AU - Jonas, Beth M.

AU - Lindsay, Theodore H.

AU - Halvorson, Kyle G.

AU - Ghilardi, Joseph R.

AU - Kuskowski, Michael A.

AU - Mukherjee, Pinku

AU - Maggio, John E.

AU - Mantyh, Patrick W

PY - 2006/9

Y1 - 2006/9

N2 - Background & Aims: The endogenous opioid system is involved in modulating the experience of pain, the response to stress, and the action of analgesic therapies. Recent human imaging studies have shown a significant tonic modulation of visceral pain, raising the question of whether endogenous opioids tonically modulate the pain of visceral cancer. Methods: Transgenic mice expressing the first 127 amino acids of simian virus 40 large T antigen, under the control of the rat elastase-1 promoter, that spontaneously develop pancreatic cancer were used to investigate the role of endogenous opioids in the modulation of pancreatic cancer pain. Visceral pain behaviors were assessed as degree of hunching and vocalization. Results Although mice with late-stage pancreatic cancer displayed spontaneous, morphine-reversible, visceral pain-related behaviors such as hunching and vocalization, these behaviors were absent in mice with early-stage pancreatic cancer. After systemic administration of the central nervous system (CNS)-penetrant opioid receptor antagonists naloxone or naltrexone, mice with early-stage pancreatic cancer displayed significant visceral pain-related behaviors, whereas systemic administration of the CNS-nonpenetrant opioid antagonist naloxone-methiodide did not induce an increase in visceral pain behaviors. Conclusions Our findings suggest that a CNS opioid-dependent mechanism tonically modulates early and late-stage pancreatic cancer pain. Understanding the mechanisms that mask this pain in early stage disease and drive this pain in late-stage disease may allow improved diagnosis, treatment, and care of patients with pancreatic cancer.

AB - Background & Aims: The endogenous opioid system is involved in modulating the experience of pain, the response to stress, and the action of analgesic therapies. Recent human imaging studies have shown a significant tonic modulation of visceral pain, raising the question of whether endogenous opioids tonically modulate the pain of visceral cancer. Methods: Transgenic mice expressing the first 127 amino acids of simian virus 40 large T antigen, under the control of the rat elastase-1 promoter, that spontaneously develop pancreatic cancer were used to investigate the role of endogenous opioids in the modulation of pancreatic cancer pain. Visceral pain behaviors were assessed as degree of hunching and vocalization. Results Although mice with late-stage pancreatic cancer displayed spontaneous, morphine-reversible, visceral pain-related behaviors such as hunching and vocalization, these behaviors were absent in mice with early-stage pancreatic cancer. After systemic administration of the central nervous system (CNS)-penetrant opioid receptor antagonists naloxone or naltrexone, mice with early-stage pancreatic cancer displayed significant visceral pain-related behaviors, whereas systemic administration of the CNS-nonpenetrant opioid antagonist naloxone-methiodide did not induce an increase in visceral pain behaviors. Conclusions Our findings suggest that a CNS opioid-dependent mechanism tonically modulates early and late-stage pancreatic cancer pain. Understanding the mechanisms that mask this pain in early stage disease and drive this pain in late-stage disease may allow improved diagnosis, treatment, and care of patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=33748278926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748278926&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2006.06.021

DO - 10.1053/j.gastro.2006.06.021

M3 - Article

C2 - 16952558

AN - SCOPUS:33748278926

VL - 131

SP - 900

EP - 910

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -